AzTrials
AzTrials

Rheumatoid ArthritisPhase 2NCT01373151

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

A Phase 2 study testing BMS-945429 and Methotrexate in people with Rheumatoid Arthritis, run by CSL Behring at 100 sites in 19 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
BMS-945429 and Methotrexate
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
418 participants
Where
100 sitesin 19 countries
Study dates
Jun 2011to Jun 2015
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Inadequate response to Methotrexate
  • Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization
  • American College of Rheumatology (ACR) global function status class 1-3
  • Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist
  • High sensitivity C-reactive protein (hsCRP) ≥ 0.8 mg/dL

Who cannot join

  • Previously received or currently receiving concomitant biologic therapy

Trial locations and contacts

100 sites in 19 countries.

100 sites in 19 countries

Japan14 sites
  • Local Institution

    Bunkyo-ku, Tokyo, 1138519

  • Local Institution

    Chiba, Chiba, 2608712

  • Local Institution

    Higashi-hiroshima-shi, Hiroshima, 7390002

  • Local Institution

    Kato-shi, Hyōgo, 6731462

  • Local Institution

    Kitakyushu-shi, Fukuoka, 8078555

  • Local Institution

    Miyazaki, Miyazaki, 8800122

  • Local Institution

    Nagano, Nagano, 3808582

  • Local Institution

    Nagasaki, Nagasaki, 8528501

  • Local Institution

    Osaka, Osaka, 5458586

  • Local Institution

    Sasebo-shi, Nagasaki, 8571195

  • Local Institution

    Shinjuku-Ku, Tokyo, 1608582

  • Local Institution

    Shizuoka, Shizuoka, 4208623

  • Local Institution

    Tomigusuku-shi, Okinawa, 9010243

  • Local Institution

    Toshima-ku, Tokyo, 1708476

Other trials in Japan

United States13 sites
  • East Penn Rheumatology Associates, P.C.

    Bethlehem, Pennsylvania, 18015

  • Box Arthritis And Rheumatology Of The Carolinas, Pllc

    Charlotte, North Carolina, 28210

  • Altoona Center For Clinical Research

    Duncansville, Pennsylvania, 16635

  • Arthritis Associates Of Mississippi

    Jackson, Mississippi, 39202

  • Physician Research Collaboration, Llc

    Lincoln, Nebraska, 68516

  • Health Research Of Oklahoma

    Oklahoma City, Oklahoma, 73103

  • Sun Valley Arthritis Center, Ltd.

    Peoria, Arizona, 85381

  • Quincy Medical Group

    Quincy, Illinois, 62301

  • Rockford Orthopedic Associates, Llc.

    Rockford, Illinois, 61107

  • San Diego Arthritis Medical Clinic

    San Diego, California, 92108

  • Seattle Rheumatology Associates

    Seattle, Washington, 98104

  • New England Research Associates, Llc

    Trumbull, Connecticut, 06611

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01605

Other trials in United States

Argentina8 sites
  • Local Institution

    Capital Federal, Buenos Aires, 1015

  • Local Institution

    Capital Federal, Buenos Aires, 1425

  • Local Institution

    Capital Federal, Buenos Aires, 1428

  • Local Institution

    Capital Federal, Buenos Aires, 1431

  • Local Institution

    Córdoba, 5000

  • Local Institution

    Rosario, Santa Fe Province, 2000

  • Local Institution

    San Juan, 5400

  • Local Institution

    San Miguel de Tucumán, Tucumán Province, 4000

Other trials in Argentina

Brazil7 sites
  • Local Institution

    Curitiba, Paraná, 80060

  • Local Institution

    Curitiba, Paraná, 80440

  • Local Institution

    Goiânia, Goiás, 74110

  • Local Institution

    Juiz de Fora, Minas Gerais, 36010

  • Local Institution

    Porto Alegre, Rio Grande do Sul, 91610

  • Local Institution

    São Paulo, 04032

  • Local Institution

    São Paulo, 04266

Other trials in Brazil

Mexico7 sites
  • Local Institution

    Culiacán, Sinaloa, 80230

  • Local Institution

    Guadalajara, Jalisco, 42650

  • Local Institution

    Guadalajara, Jalisco, 45040

  • Local Institution

    Mexico City, Mexico City, 11850

  • Local Institution

    Monterrey, Nuevo León, 64020

  • Local Institution

    Morelia, Michioacan, 58270

  • Local Institution

    San Luis Potosí City, 78213

Other trials in Mexico

Russia6 sites
  • Local Institution

    Kazan', 420064

  • Local Institution

    Moscow, 115522

  • Local Institution

    Novosibirsk, 630005

  • Local Institution

    Saint Petersburg, 191014

  • Local Institution

    Yaroslavl, 150003

  • Local Institution

    Yekaterinburg, 620102

Other trials in Russia

South Africa6 sites
  • Local Institution

    Durban, KwaZulu-Natal, 4001

  • Local Institution

    Panorama, Western Cape, 7500

  • Local Institution

    Pinelands, Cape Town, Western Cape, 7405

  • Local Institution

    Pretoria, Gauteng, 0083

  • Local Institution

    Pretoria, Gauteng, 0132

  • Local Institution

    Tygerberg, Western Cape, 7505

Other trials in South Africa

Poland5 sites
  • Local Institution

    Katowice, 40-748

  • Local Institution

    Krakow, 31-531

  • Local Institution

    Poznan, 60773

  • Local Institution

    Warsaw, 01-868

  • Local Institution

    Warsaw, 02-118

Other trials in Poland

Spain5 sites
  • Local Institution

    A Coruña, 15006

  • Local Institution

    Madrid, 28040

  • Local Institution

    Santander, 39008

  • Local Institution

    Santiago de Compostela, 15706

  • Local Institution

    Seville, 41071

Other trials in Spain

Germany4 sites
  • Local Institution

    Berlin, 14059

  • Local Institution

    Cologne, 50931

  • Local Institution

    Leipzig, 04103

  • Local Institution

    Würzburg, 97080

Other trials in Germany

Hungary4 sites
  • Local Institution

    Budapest, 1027

  • Local Institution

    Debrecen, 4012

  • Local Institution

    Gyula, 5700

  • Local Institution

    Veszprém, 8200

Other trials in Hungary

Taiwan4 sites
  • Local Institution

    Changhua, 500

  • Local Institution

    Kaohsiung City, 833

  • Local Institution

    Taichung, 404

  • Local Institution

    Taoyuan, 333

Other trials in Taiwan

Canada3 sites
  • Local Institution

    Montreal, Quebec, H2L 1S6

  • Local Institution

    Québec, Quebec, G1W 4R4

  • Centre De Recherche Musculo-Squelettique

    Trois-Rivières, Quebec, G8Z 1Y2

Other trials in Canada

France3 sites
  • Local Institution

    Bordeaux, 33076

  • Local Institution

    Chambray-lès-Tours, 37170

  • Local Institution

    Strasbourg, 67098

Other trials in France

Italy3 sites
  • Local Institution

    Naples, 80131

  • Local Institution

    Padova, 35128

  • Local Institution

    Reggio Emilia, 42100

Other trials in Italy

South Korea3 sites
  • Local Institution

    Daegu, 705-718

  • Local Institution

    Seoul, 133-792

  • Local Institution

    Seoul, 137-701

Other trials in South Korea

Belgium2 sites
  • Local Institution

    Brussels, 1200

  • Local Institution

    Hasselt, 3500

Other trials in Belgium

Czechia2 sites
  • Local Institution

    Prague, 128 50

  • Local Institution

    Prague, 140 59

Other trials in Czechia

Netherlands1 site
  • Local Institution

    Amsterdam, 1056 AB

Other trials in Netherlands

About this study

Official title: A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.

The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.

Being tested
BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BMS-945429 PlaceboDrug

    Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only

  • BMS-945429Biological

    Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only

  • BMS-945429Biological

    Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks

  • BMS-945429Biological

    Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48

  • BMS-945429Biological

    Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks

  • MethotrexateDrug

    Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only

  • MethotrexateDrug

    Tablets, Oral, 15 mg, Weekly, 48 weeks

  • Methotrexate PlaceboDrug

    Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only

  • MethotrexateDrug

    Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only

  • Adalimumab PlaceboDrug

    Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks

  • AdalimumabDrug

    Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks

Study groups in NCT01373151
Study groupRoleWhat they receive
Arm 1Placebo comparatorBMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
Receives: Drug: BMS-945429 Placebo; Biological: BMS-945429; Drug: Methotrexate; Drug: Adalimumab Placebo
Arm 2ExperimentalBMS-945429 + Methotrexate + Adalimumab Placebo
Receives: Biological: BMS-945429; Drug: Methotrexate; Drug: Adalimumab Placebo
Arm 3ExperimentalBMS-945429 + Methotrexate + Adalimumab Placebo
Receives: Biological: BMS-945429; Drug: Methotrexate; Drug: Adalimumab Placebo
Arm 4ExperimentalBMS-945429 + Methotrexate + Adalimumab Placebo
Receives: Biological: BMS-945429; Drug: Methotrexate; Drug: Adalimumab Placebo
Arm 5ExperimentalBMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
Receives: Biological: BMS-945429; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo
Arm 6ExperimentalBMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
Receives: Biological: BMS-945429; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo
Arm 7Active comparatorAdalimumab + Methotrexate
Receives: Drug: Methotrexate; Drug: Adalimumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Measured: At 12 Weeks

Secondary outcomes (16)
  1. Percent of Participants With ACR 20 Response

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Measured: At 24 weeks

  2. Percent of Participants Achieving ACR 50 Response Rate

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Measured: At weeks 12 and 24

  3. Percent of Participants Achieving ACR 70 Response Rate

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Measured: At weeks 12 and 24

  4. Mean Change From Baseline in Disease Activity as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)

    DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.

    Measured: Baseline, weeks 12 and 24

  5. Percent of Participants With Remission by DAS28-CRP

    DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.

    Measured: At weeks 12 and 24

  6. Mean Change From Baseline in Clinical Disease Activity Index (CDAI)

    CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76.

    CDAI <= 2.8 = Remission CDAI > 2.8 and <= 10 = Low Disease Activity CDAI > 10 and <= 22 = Moderate Disease Activity CDAI > 22 = High Disease Activity

    Measured: Baseline, weeks 12 and 24

  7. Percent of Participants With Remission by CDAI

    CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76.

    CDAI <= 2.8 = Remission CDAI > 2.8 and <= 10 = Low Disease Activity CDAI > 10 and <= 22 = Moderate Disease Activity CDAI > 22 = High Disease Activity

    Measured: At weeks 12 and 24

  8. Mean Change From Baseline in Simplified Disease Activity Index (SDAI)

    SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86.

    0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity

    Measured: Baseline, weeks 12 and 24

  9. Percent of Participants With Remission by SDAI

    SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86.

    0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity

    Measured: At weeks 12 and 24

  10. Percent of Participants With Remission Rate by Boolean Definition

    Boolean-based definition:

    At any time point, a patient must satisfy all of the following:

    TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)

    Measured: At weeks 12 and 24

  11. Mean Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index

    Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.

    Measured: Baseline, weeks 12 and 24

  12. Mean Change From Baseline in Short Form 36 (SF-36) as Measured by Physical and Mental Components

    The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.

    Measured: Baseline, weeks 12 and 24

  13. Mean Change From Baseline in Fatigue Severity (VAS) Score

    A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.

    Measured: Baseline, weeks 12 and 24

  14. Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Scores

    The WPAI yeilds four types of scores:

    1. Absenteeism (work time missed)
    2. Presenteesism (impairment at work / reduced on-the-job effectiveness)
    3. Work productivty loss (overall work impairment / absenteeism plus presenteeism)
    4. Activity Impairment WPAI outcomes are expressed as impairment percentages with each subscale score ranging from 0-100. The subscale scores are added and averaged to produce a total WPAI score between 0-100. Higher scores indicate greater impairment and less productivity.

    Measured: Baseline, weeks 12 and 24

  15. Mean Change From Baseline in Radiographic (MRI) Progression of Synovitis, Osteitis (Bone Marrow Edema), Bone Erosion and Cartilage Loss (Joint-space Narrowing)

    Measured: Baseline and week 12

  16. Mean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score

    The Sharp-van der Heijde total score ranges from 0-528. Scores for erosion range from 0 to 5 in the hands and 0 to 10 in the feet and reflect erosion size, with 0 defined as no erosion and 3 defined as a large erosion passing the midline of the joint. If there is > 1 erosion per joint, scores can be combined to give a maximum score of 5 per joint in the hands and 10 per joint in the feet (a maximum of 5 at each side of the joint). Joint space narrowing scores vary from 0 to 4 in both the hands and feet, with 0 being normal and 4 being the absence of joint space with evident ankylosis or subluxation. Gross osteolysis and pencil-in-cup change are scored separately and, if present, are assigned the maximum score for erosion and joint space narrowing for the same affected joint. Higher scores indicate increased joint damage.

    Measured: Baseline and week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2011 (estimated)
  2. Study startJun 2011
  3. Primary completionSep 2012
  4. Study completionJun 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
418 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01373151
Sponsor's protocol ID
IM133-001
Other IDs
2010-023956-99
Status last verified
Nov 2021
First submitted
13 Jun 2011
Last updated
6 Dec 2021
Data monitoring committee
Yes

Publications

  • Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015 Oct;67(10):2591-600. doi: 10.1002/art.39249.

    PubMed 26138593

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BMS-945429 and Methotrexate in people with Rheumatoid Arthritis, run by CSL Behring at 100 sites in 19 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 100 sites in Japan, United States, Argentina, Brazil, Mexico and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Dec 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate (time frame: At 12 Weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01373151, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT01373151 | AzTrials